$17.82 -0.32 (-1.79%)

UroGen Pharma Ltd. Ordinary Shares (URGN)

UroGen Pharma Ltd. is a biotechnology company focused on developing innovative solutions for urological and uro-oncological conditions. The company's portfolio includes targeted therapies designed to improve treatment outcomes for patients with conditions such as bladder cancer and other genitourinary diseases. UroGen aims to leverage advanced drug delivery technologies to enhance safety and efficacy in urological treatments.

Company News

ZUSDURI™ Clinical Review Published in Reviews in Urology™ Highlights Durable Efficacy and Manageable Safety Profile in Recurrent Low-Grade, Intermediate-Risk Non–Muscle Invasive Bladder Cancer

GlobeNewswire Inc. • Urogen Pharma Ltd. • October 2, 2025

UroGen Pharma published a comprehensive review highlighting the clinical efficacy of ZUSDURI, an FDA-approved treatment for recurrent low-grade, intermediate-risk non-muscle invasive bladder cancer, demonstrating high complete response rates and a manageable safety profile.

Securities Fraud Investigation Into UroGen Pharma Ltd. (URGN) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

Benzinga • Business Wire • May 16, 2025

The U.S. Food and Drug Administration (FDA) questioned the efficacy and utility of UroGen Pharma's experimental bladder cancer therapy UGN-102, causing the company's stock price to fall significantly.

Urogen Pharma (URGN) Surges 9.7%: Is This an Indication of Further Gains?

Zacks Investment Research • Zacks Equity Research • June 17, 2024

Urogen Pharma (URGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

RGNX

Why Shares of UroGen Pharma Jumped Friday

The Motley Fool • [email protected] (Jim Halley) • July 28, 2023

The company released positive top-line results for two studies for a bladder cancer treatment.